Clinical Trial Results:
Sorafenib in Resected NSCLC (SIRN) - A Phase II Study to Investigate the Efficacy and Safety of Sorafenib as Adjuvant Treatment following Resection of Non-small Cell Lung Carcinoma (NSCLC) in Patients not eligible for Cisplatin-based Adjuvant Chemotherapy
Summary
|
|
EudraCT number |
2006-006566-42 |
Trial protocol |
DE |
Global completion date |
15 Jul 2008
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
13 Mar 2020
|
First version publication date |
13 Mar 2020
|
Other versions |
|
Summary report(s) |
Report Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.